Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
5.72
+0.11 (1.96%)
At close: Jun 18, 2026, 4:00 PM EDT
5.83
+0.11 (1.92%)
After-hours: Jun 18, 2026, 7:38 PM EDT
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $9.13M in the quarter ending March 31, 2026, a decrease of -22.04%. This brings the company's revenue in the last twelve months to $41.94M, up 2.08% year-over-year. In the year 2025, Cumberland Pharmaceuticals had annual revenue of $44.52M with 17.57% growth.
Revenue (ttm)
$41.94M
Revenue Growth
+2.08%
P/S Ratio
1.98
Revenue / Employee
$450,964
Employees
93
Market Cap
85.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.52M | 6.65M | 17.57% |
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
| Dec 31, 2018 | 29.34M | -11.81M | -28.69% |
| Dec 31, 2017 | 41.15M | 8.12M | 24.60% |
| Dec 31, 2016 | 33.03M | -493.50K | -1.47% |
| Dec 31, 2015 | 33.52M | -3.38M | -9.17% |
| Dec 31, 2014 | 36.90M | 4.87M | 15.22% |
| Dec 31, 2013 | 32.03M | -16.82M | -34.44% |
| Dec 31, 2012 | 48.85M | -2.29M | -4.48% |
| Dec 31, 2011 | 51.14M | 5.27M | 11.48% |
| Dec 31, 2010 | 45.88M | 2.34M | 5.37% |
| Dec 31, 2009 | 43.54M | 8.46M | 24.13% |
| Dec 31, 2008 | 35.08M | 7.01M | 24.98% |
| Dec 31, 2007 | 28.06M | 10.25M | 57.52% |
| Dec 31, 2006 | 17.82M | 7.13M | 66.66% |
| Dec 31, 2005 | 10.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 229.67M |
| Organigram Global | 196.43M |
| InterCure | 84.76M |
| Journey Medical | 64.68M |
| BGM Group | 25.10M |
| SCYNEXIS | 20.34M |
| BioXcel Therapeutics | 680.00K |
| Incannex Healthcare | 12.00K |
CPIX News
- 20 hours ago - RedHill Biopharma Announces Up To $19.4 Million Private Placement - PRNewsWire
- 9 days ago - RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation - PRNewsWire
- 10 days ago - RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo - PRNewsWire
- 16 days ago - Cumberland announces data from Phase 2a clinical trial of ifetroban - TheFly
- 16 days ago - Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis - PRNewsWire
- 16 days ago - RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms - PRNewsWire
- 21 days ago - Cumberland announces launch of Vibativ in China - TheFly
- 21 days ago - CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA - PRNewsWire